Table 3 Second set of inhibitors, docking scores and PASA.
From: Peptidomimetics designed to bind to RAS effector domain are promising cancer therapeutic compounds
From: Peptidomimetics designed to bind to RAS effector domain are promising cancer therapeutic compounds